# Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers

> **NCT02221388** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 671800 HEA, 200 mg tablets
- **DRUG:** BI 671800 HEA EC, 200 mg tablets
- **DRUG:** BI 671800 HEA, 50 mg tablets
- **DRUG:** BI 671800 ED, 100 mg capsules
- **OTHER:** Standard meal

## Key facts

- **NCT ID:** NCT02221388
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-07
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02221388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02221388, "Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT02221388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*